Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer

[1]  N. Robert,et al.  Estrogen Replacement Therapy in Breast Cancer Survivors-Reply , 1995 .

[2]  R. Santen,et al.  In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. , 1984, The Journal of clinical endocrinology and metabolism.

[3]  H. Mouridsen,et al.  Treatment of advanced breast cancer with tamoxifen: Evaluation of the dose-response relationship at two dose levels , 1982, Breast Cancer Research and Treatment.

[4]  B. Stadel,et al.  Estrogen replacement therapy in breast cancer survivors. , 1995, JAMA.

[5]  T. Powles,et al.  Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Cummings,et al.  Hormone therapy to prevent disease and prolong life in postmenopausal women , 1992, Annals of internal medicine.

[7]  S J Pocock,et al.  Long-term survival of patients with breast cancer: a study of the curability of the disease. , 1979, British medical journal.

[8]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[9]  K. Anderson,et al.  Abnormal oxidative metabolism of estradiol in women with breast cancer. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[10]  C. Redmond,et al.  Endocrine treatment of breast cancer in women. , 1990, Endocrine reviews.

[11]  M. Reed,et al.  Multiple forms of 17β-hydroxysteroid oxidoreductase in human breast tissue , 1989 .

[12]  P. Lønning,et al.  Clinical Pharmacokinetics of Endocrine Agents Used in Advanced Breast Cancer , 1992, Clinical pharmacokinetics.

[13]  B. Furr,et al.  The pharmacology and clinical uses of tamoxifen. , 1984, Pharmacology & therapeutics.

[14]  A. Huvos,et al.  Castration for primary inoperable or recurrent breast carcinoma. , 1969, Surgery, gynecology & obstetrics.

[15]  P. Strax,et al.  A prospective study of endogenous estrogens and breast cancer in postmenopausal women. , 1995, Journal of the National Cancer Institute.

[16]  N. Robert,et al.  Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. , 1994, JAMA.

[17]  H. Høst,et al.  Age as a prognostic factor in breast cancer , 1986, Cancer.

[18]  R. Theriault,et al.  Randomized prospective trial of estrogen-replacement therapy in women with a history of breast cancer. , 1994, Journal of the National Cancer Institute. Monographs.

[19]  J. Dwyer,et al.  Estrogen metabolism and excretion in Oriental and Caucasian women. , 1994, Journal of the National Cancer Institute.

[20]  N. Robert,et al.  Estrogen Replacement Therapy in Breast Cancer Survivors: A Time for Change , 1994 .

[21]  T. Eberlein,et al.  Height, weight, and risk of breast cancer relapse , 1985, Breast Cancer Research and Treatment.

[22]  D. Gordon.  WOODPECKERS' TONGUES , 1976, The Lancet.

[23]  G. Beatson.  On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases , 1896, Transactions. Medico-Chirurgical Society of Edinburgh.

[24]  Earlybreastcancertrialistscol,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.

[25]  P. Lønning,et al.  Relations between sex hormones, sex hormone binding globulin, insulin‐like growth factor‐I and insulin‐like growth factor binding protein‐I in post‐menopausal breast cancer patients , 1995, Clinical endocrinology.

[26]  H. Adlercreutz,et al.  The multicomponent analysis of estrogens in urine by ion exchange chromatography and GC-MS--I. Quantitation of estrogens after initial hydrolysis of conjugates. , 1987, Journal of steroid biochemistry.

[27]  H. Adami,et al.  Age as a prognostic factor in breast cancer , 1985, Cancer.

[28]  R. Gambrell.  Proposal to decrease the risk and improve the prognosis of breast cancer. , 1984, American journal of obstetrics and gynecology.